Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium […]
NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR
Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that […]
Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
NERVIANO, 21 September 2022 Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 […]
Nerviano Medical Sciences S.r.l. Expands US Presence
Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated […]
Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).
Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult patients with relapsed refractory Multiple Myeloma (MM). NMS-812 is a novel potent […]
NMS Group S.p.A. has approved the 2021 Financial Statements with positive outlook for 2022
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021. “2021 was a challenging yet rewarding year for our Group. As we firmly believe in our mission to discover and develop life-changing molecules to patients, we […]
European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS S.r.l.
Nerviano, 13 May 2022 MPS1, also known as monopolar spindle 1, is a protein kinase which is over-expressed and hyperactivated in different tumors and which plays a critical role in the control of mitosis (cell division) by regulating a process called the Spindle Assembly Checkpoint. NMS Srl started the MPS1 inhibitor program, which resulted in […]
Nerviano Medical Sciences announces new organizational structure and management team including key appointments
Nerviano, 5 May 2022 Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancers, today announces the new organizational structure and key appointments of the new management team, effective immediately. The new organizational structure is designed to: Reposition the company’s […]
Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy
Nerviano, 7 February 2022 NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione […]
NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
Nerviano, 17 January 2022 The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato. Dr. Dolgos joins from […]
